0 287

Cited 84 times in

Immunotherapy in the treatment of non-small cell lung cancer

DC Field Value Language
dc.contributor.author조병철-
dc.date.accessioned2015-01-06T17:13:48Z-
dc.date.available2015-01-06T17:13:48Z-
dc.date.issued2014-
dc.identifier.issn0169-5002-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/99580-
dc.description.abstractAdvances in the understanding of the role of the immune system in tumor immunosurveillance have resulted in the recognition that tumors can evade immune destruction via the dysregulation of co-inhibitory or checkpoint signals. This has led to the development of a generation immunotherapeutic agents targeting the immune checkpoint pathway. Recent early phase studies of immune checkpoint modulators, such as CTLA-4, PD-1 and PD-L1 inhibitors in NSCLC have reported promising results with prolonged clinical responses and tolerable toxicity. This article provides an overview of co-stimulatory and inhibitory molecules that regulate the immune response to tumors, recent therapies that have been developed to exploit these interactions and the role of predictive biomarkers in treatment selection.-
dc.description.statementOfResponsibilityopen-
dc.format.extent101~109-
dc.relation.isPartOfLUNG CANCER-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.rights.urihttps://creativecommons.org/licenses/by-nc-nd/2.0/kr/-
dc.subject.MESHAnimals-
dc.subject.MESHAntibodies, Monoclonal/therapeutic use-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung/genetics-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung/immunology*-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung/metabolism-
dc.subject.MESHCarcinoma, Non-Small-Cell Lung/therapy*-
dc.subject.MESHCarrier Proteins/metabolism-
dc.subject.MESHCostimulatory and Inhibitory T-Cell Receptors/genetics-
dc.subject.MESHCostimulatory and Inhibitory T-Cell Receptors/metabolism-
dc.subject.MESHHumans-
dc.subject.MESHImmunotherapy*-
dc.subject.MESHLung Neoplasms/genetics-
dc.subject.MESHLung Neoplasms/immunology*-
dc.subject.MESHLung Neoplasms/metabolism-
dc.subject.MESHLung Neoplasms/therapy*-
dc.subject.MESHProtein Binding-
dc.titleImmunotherapy in the treatment of non-small cell lung cancer-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Internal Medicine (내과학)-
dc.contributor.googleauthorRaghav Sundar-
dc.contributor.googleauthorRichie Soong-
dc.contributor.googleauthorByoung-Chul Cho-
dc.contributor.googleauthorJulie R. Brahmer-
dc.contributor.googleauthorRoss A. Soo-
dc.identifier.doi10.1016/j.lungcan.2014.05.005-
dc.admin.authorfalse-
dc.admin.mappingfalse-
dc.contributor.localIdA03822-
dc.relation.journalcodeJ02174-
dc.identifier.eissn1872-8332-
dc.identifier.pmid24880938-
dc.identifier.urlhttp://www.sciencedirect.com/science/article/pii/S0169500214002141-
dc.subject.keywordCTLA-4-
dc.subject.keywordImmunotherapy-
dc.subject.keywordIpilimumab-
dc.subject.keywordNivolumab-
dc.subject.keywordNon-small cell lung cancer-
dc.subject.keywordPD-L1-
dc.contributor.alternativeNameCho, Byoung Chul-
dc.contributor.affiliatedAuthorCho, Byoung Chul-
dc.rights.accessRightsfree-
dc.citation.volume85-
dc.citation.number2-
dc.citation.startPage101-
dc.citation.endPage109-
dc.identifier.bibliographicCitationLUNG CANCER, Vol.85(2) : 101-109, 2014-
dc.identifier.rimsid38932-
dc.type.rimsART-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.